Patricia Murray uncovers the business secrets of the Nobelist Martin Evans and his partner Ajan Reginald. It seems the magic iMP cells used to treat patients in Greece were drawn from the blood of patients in Swansea, for the purpose of a secret PhD thesis. There is no serious science behind it, only serious investor money and a fraudulent patent.
Sir Martin Evans, winner of Nobel prize 2007, founded in 2009 the stem cell start-up Celixir, together with a struck-off dentist Ajan Reginald. With the help of the British heart surgeon Stephen Westaby, they ran a very profitable clinical trial in Greece, which now moved into UK.
A PhD thesis was defended in 2017 at CNRS plant science institute IBMP in Strasbourg, it tested the anti-flu product L52 by the French homeopathy manufacturer Lehning Laboratories. The homeopathic concoction was found very effective, with potential use for human health!
The World Health Organisation (WHO) has a cancer research unit in France, IARC. Some papers from there contain impressive manipulations. The works of art are authored by Massimo Tommasino and his former junior colleague there Uzma Hasan, now tenured group leader at INSERM. Some of this research took place at the Schering-Plough Research Institute which was taken over by German pharma giant Merck.
Louis J. Ignarro knew how to monetize his 1998 Nobel Prize for discovery of nitric oxide as molecular cell signalling agent. He made many millions selling dietary supplement for Herbalife and pomegranate juice for POM Wonderful Company. Some of that found its way (without proper conflict of interest declaration) into Ignarro’s peer reviewed papers. Those, done in collaboration with certain Photoshop artists like Claudio Napoli, contain clearly fabricated data.
Janine Erler is a star of Danish cancer research, funded by ERC. Her earlier research led to the discovery of the key role of the enzyme lysyl oxidase in cancer metastasis and brought the scientist and businesswoman very close to curing cancer. Until some sad envious bad-wishers found duplicated gel bands in Erler papers.
What with the EU phase 2 clinical trial TETRA going nowhere, the technology’s owner, Liverpool-based company Videregen decided to seek new clinical partners. Surgeons and universities from outside the EU are invited to test Videregen’s trachea transplant technology, which was originally developed together with Paolo Macchiarini by the UCL laryngologist and paid Videregen advisor Martin Birchall.
The European Commission admitted that their €6.8 mn phase 2 clinical trial TETRA with cadaveric tracheas, led by the UCL laryngologist Martin Birchall is unlikely to ever recruit any patients. In January 2019, the status was changed to “grant agreement terminated”